154 related articles for article (PubMed ID: 18504399)
1. Mechanism for the decrease in the FIP1L1-PDGFRalpha protein level in EoL-1 cells by histone deacetylase inhibitors.
Ishihara K; Kaneko M; Kitamura H; Takahashi A; Hong JJ; Seyama T; Iida K; Wada H; Hirasawa N; Ohuchi K
Int Arch Allergy Immunol; 2008; 146 Suppl 1():7-10. PubMed ID: 18504399
[TBL] [Abstract][Full Text] [Related]
2. Mechanism for the differentiation of EoL-1 cells into eosinophils by histone deacetylase inhibitors.
Kaneko M; Ishihara K; Takahashi A; Hong J; Hirasawa N; Zee O; Ohuchi K
Int Arch Allergy Immunol; 2007; 143 Suppl 1():28-32. PubMed ID: 17541273
[TBL] [Abstract][Full Text] [Related]
3. Differentiation of eosinophilic leukemia EoL-1 cells into eosinophils induced by histone deacetylase inhibitors.
Ishihara K; Takahashi A; Kaneko M; Sugeno H; Hirasawa N; Hong J; Zee O; Ohuchi K
Life Sci; 2007 Mar; 80(13):1213-20. PubMed ID: 17258775
[TBL] [Abstract][Full Text] [Related]
4. Mechanisms for the proliferation of eosinophilic leukemia cells by FIP1L1-PDGFRalpha.
Ishihara K; Kitamura H; Hiraizumi K; Kaneko M; Takahashi A; Zee O; Seyama T; Hong J; Ohuchi K; Hirasawa N
Biochem Biophys Res Commun; 2008 Feb; 366(4):1007-11. PubMed ID: 18086564
[TBL] [Abstract][Full Text] [Related]
5. Possible mechanism of action of the histone deacetylase inhibitors for the induction of differentiation of HL-60 clone 15 cells into eosinophils.
Ishihara K; Hong J; Zee O; Ohuchi K
Br J Pharmacol; 2004 Jul; 142(6):1020-30. PubMed ID: 15210580
[TBL] [Abstract][Full Text] [Related]
6. The EOL-1 cell line as an in vitro model for the study of FIP1L1-PDGFRA-positive chronic eosinophilic leukemia.
Cools J; Quentmeier H; Huntly BJ; Marynen P; Griffin JD; Drexler HG; Gilliland DG
Blood; 2004 Apr; 103(7):2802-5. PubMed ID: 14630792
[TBL] [Abstract][Full Text] [Related]
7. Dasatinib inhibits the growth and survival of neoplastic human eosinophils (EOL-1) through targeting of FIP1L1-PDGFRalpha.
Baumgartner C; Gleixner KV; Peter B; Ferenc V; Gruze A; Remsing Rix LL; Bennett KL; Samorapoompichit P; Lee FY; Pickl WF; Esterbauer H; Sillaber C; Superti-Furga G; Valent P
Exp Hematol; 2008 Oct; 36(10):1244-53. PubMed ID: 18619723
[TBL] [Abstract][Full Text] [Related]
8. Sorafenib is a potent inhibitor of FIP1L1-PDGFRalpha and the imatinib-resistant FIP1L1-PDGFRalpha T674I mutant.
Lierman E; Folens C; Stover EH; Mentens N; Van Miegroet H; Scheers W; Boogaerts M; Vandenberghe P; Marynen P; Cools J
Blood; 2006 Aug; 108(4):1374-6. PubMed ID: 16645167
[TBL] [Abstract][Full Text] [Related]
9. FIP1L1-PDGFRalpha D842V, a novel panresistant mutant, emerging after treatment of FIP1L1-PDGFRalpha T674I eosinophilic leukemia with single agent sorafenib.
Lierman E; Michaux L; Beullens E; Pierre P; Marynen P; Cools J; Vandenberghe P
Leukemia; 2009 May; 23(5):845-51. PubMed ID: 19212337
[TBL] [Abstract][Full Text] [Related]
10. Identification of Ponatinib as a potent inhibitor of growth, migration, and activation of neoplastic eosinophils carrying FIP1L1-PDGFRA.
Sadovnik I; Lierman E; Peter B; Herrmann H; Suppan V; Stefanzl G; Haas O; Lion T; Pickl W; Cools J; Vandenberghe P; Valent P
Exp Hematol; 2014 Apr; 42(4):282-293.e4. PubMed ID: 24407160
[TBL] [Abstract][Full Text] [Related]
11. [The activation of JAK/STAT signal pathway in hypereosinophilic syndrome and the patients therapeutic response to imatinib].
Li B; Zhang GS; Dai CW; Pei MF
Zhonghua Yi Xue Za Zhi; 2005 Feb; 85(7):448-52. PubMed ID: 15854548
[TBL] [Abstract][Full Text] [Related]
12. Triptolide abrogates oncogene FIP1L1-PDGFRalpha addiction and induces apoptosis in hypereosinophilic syndrome.
Jin Y; Chen Q; Lu Z; Chen B; Pan J
Cancer Sci; 2009 Nov; 100(11):2210-7. PubMed ID: 19671059
[TBL] [Abstract][Full Text] [Related]
13. FIP1L1-PDGFRalpha imposes eosinophil lineage commitment on hematopoietic stem/progenitor cells.
Fukushima K; Matsumura I; Ezoe S; Tokunaga M; Yasumi M; Satoh Y; Shibayama H; Tanaka H; Iwama A; Kanakura Y
J Biol Chem; 2009 Mar; 284(12):7719-32. PubMed ID: 19147501
[TBL] [Abstract][Full Text] [Related]
14. FIP1L1-PDGFRA in chronic eosinophilic leukemia and BCR-ABL1 in chronic myeloid leukemia affect different leukemic cells.
Crescenzi B; Chase A; Starza RL; Beacci D; Rosti V; Gallì A; Specchia G; Martelli MF; Vandenberghe P; Cools J; Jones AV; Cross NC; Marynen P; Mecucci C
Leukemia; 2007 Mar; 21(3):397-402. PubMed ID: 17215855
[TBL] [Abstract][Full Text] [Related]
15. Eosinophil cell lines.
Ishihara K
Methods Mol Biol; 2014; 1178():45-51. PubMed ID: 24986606
[TBL] [Abstract][Full Text] [Related]
16. S100A8 and S100A9 Promote Apoptosis of Chronic Eosinophilic Leukemia Cells.
Lee JS; Lee NR; Kashif A; Yang SJ; Nam AR; Song IC; Gong SJ; Hong MH; Kim G; Seok PR; Lee MS; Sung KH; Kim IS
Front Immunol; 2020; 11():1258. PubMed ID: 32903598
[TBL] [Abstract][Full Text] [Related]
17. The severity of FIP1L1-PDGFRA-positive chronic eosinophilic leukaemia is associated with polymorphic variation at the IL5RA locus.
Burgstaller S; Kreil S; Waghorn K; Metzgeroth G; Preudhomme C; Zoi K; White H; Cilloni D; Zoi C; Brito-Babapulle F; Walz C; Reiter A; Cross NC
Leukemia; 2007 Dec; 21(12):2428-32. PubMed ID: 17914408
[TBL] [Abstract][Full Text] [Related]
18. Molecular mechanisms underlying FIP1L1-PDGFRA-mediated myeloproliferation.
Buitenhuis M; Verhagen LP; Cools J; Coffer PJ
Cancer Res; 2007 Apr; 67(8):3759-66. PubMed ID: 17440089
[TBL] [Abstract][Full Text] [Related]
19. Synchronous FIP1L1-PDGFRA-positive chronic eosinophilic leukemia and T-cell lymphoblastic lymphoma: a bilineal clonal malignancy.
Capovilla M; Cayuela JM; Bilhou-Nabera C; Gardin C; Letestu R; Baran-Marzak F; Fenaux P; Martin A
Eur J Haematol; 2008 Jan; 80(1):81-6. PubMed ID: 18028420
[TBL] [Abstract][Full Text] [Related]
20. Ponatinib efficiently kills imatinib-resistant chronic eosinophilic leukemia cells harboring gatekeeper mutant T674I FIP1L1-PDGFRα: roles of Mcl-1 and β-catenin.
Jin Y; Ding K; Li H; Xue M; Shi X; Wang C; Pan J
Mol Cancer; 2014 Jan; 13():17. PubMed ID: 24472312
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
